North America CIN & HR-HPV Treatment Market Forecast to 2028 -Regional Analysis

The North America CIN & HR-HPV treatment market is expected to grow from US$ 4,872.99 million in 2023 to US$ 6,693.51 million by 2028. It is estimated to grow at a CAGR of 6.6% from 2023 to 2028.

Favorable Initiatives for Preventing Cervical Cancer is Fueling North America CIN & HR-HPV treatment market

In August 2020, the World Health Organization (WHO) devised a strategy for the elimination of cervical cancer. Per this strategy, all countries across the region must focus on reaching and maintaining an incidence rate of less than 4 per 100,000 women to eliminate cervical cancer. To attain such low incidence rates, countries should focus on cervical cancer screening, treatment, and vaccination. Medicare, a popular government insurance program, provides coverage for PAP tests, pelvic exams, and clinical breast examinations performed every two years for cervical cancer screening.

Unitaid, a global health agency that works to bring about innovative solutions to prevent, diagnose, and treat major diseases in low- and middle-income countries, has come up with a new initiative for cervical cancer prevention. Its efforts are focused on expanding access to critical tools and services to screen for the early signs of cervical cancer, followed by the treatment of positive cases. Unitaid is providing support for the Clinton Health Access Initiative (CHAI) and the Scale Up Cervical Cancer Elimination with Secondary Prevention Strategy (SUCCESS) Project, which are being carried out in partnership with Expertise France, Jhpiego, and the Union for International Cancer Control (UICC). Unitaid is collaborating with these partners and governments of 14 low- and middle-income countries to develop an affordable and highly effective package of tools, which can help the World Health Organization achieve its cervical cancer elimination targets. The Unitaid has invested ~US$ 70 million in innovative tools to screen women living in low-resource environments for precancer conditions and treat them. In 14 countries, Unitaid is striving to overcome access barriers and laying the groundwork for national cervical cancer elimination efforts, demonstrating effective models of prevention across low- and middle-income countries.

Such initiatives by various healthcare organizations and governments for preventing cervical cancer boost the growth of the CIN & HR-HPV treatment market.

North America CIN & HR-HPV Treatment Market Overview

The North America CIN & HR-HPV treatment market is segmented into the US, Canada, and Mexico. The US held the largest share of the market in 2022. The rising number of research and development activities, growing awareness of cervical cancer, the significant presence of healthcare giants, and initiatives by government authorities and NGOs to promote cervical cancer screening are the factors contributing to the growth of the CIN & HR-HPV treatment market.

Exhibit: North America CIN & HR-HPV Treatment Market Revenue and Forecast to 2028 (US$ Million)

North America CIN & HR-HPV Treatment Market Segmentation

The North America CIN & HR-HPV treatment market is segmented into disease type, strain type, offering, product type, end user, and country. Based on disease type, the market is subsegmented into cervical intraepithelial neoplasia 1 (CIN 1), cervical intraepithelial neoplasia 2 (CIN 2), and cervical intraepithelial neoplasia 3 (CIN 3). The cervical intraepithelial neoplasia 3 (CIN 3) segment registered the largest market share in 2023.

Based on strain type, the market is segmented into HPV 16, HPV 18, and others. The HPV 16 segment held a largest market share in 2023.

Based on offering, the market is bifurcated into diagnostic methods and treatments. The treatments segment held the largest market share in 2023. Further, diagnostic methods are segmented into pap smear, HPV testing, colposcopy, and biopsy. Further, treatments are bifurcated into excision surgery and ablation techniques.

Based on product type, the market is segmented into kits & reagents, instruments, and services. The services segment held a largest market share in 2023.

Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. The hospitals & clinics segment held a largest market share in 2023.

Based on country, the market is segmented into the US, Canada, Mexico. The US dominated the market share in 2023.

Fujirebio Europe NV; Qiagen NV; Abbott Laboratories; Cepheid; F. Hoffmann-LA Roche Ltd; INOVIO Pharmaceuticals Inc; Bioneer Corp; Antiva Biosciences Inc; and Thermo Fisher Scientific Inc are the leading companies operating in the CIN & HR-HPV treatment market in the region.